Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Frédéric Hoerner"'
Autor:
Tugba Akin Telli, Françoise Rothé, Francesco Sclafani, Caroline Vandeputte, Gabriela Critchi, Silvia Camera, Giacomo Bregni, Chiara Senti, Elena Trevisi, Yacine Wissam, Frédéric Hoerner, Amélie Deleporte, Paraskevas Gkolfakis, Andrea Pretta, Pashalina Kehagias, Patrick Flamen, Alain Hendlisz, Erwin Woff, Thomas Guiot, Sophia Leduc
Publikováno v:
Cancers
Volume 12
Issue 10
Cancers, 12 (10
Cancers, Vol 12, Iss 2752, p 2752 (2020)
Cancers (Basel), 12 (10
Volume 12
Issue 10
Cancers, 12 (10
Cancers, Vol 12, Iss 2752, p 2752 (2020)
Cancers (Basel), 12 (10
Introduction: Decision making in refractory colorectal cancer (rCRC) is challenging, with limited data available to predict patient outcome. We conducted a study to assess the pace of cancer progression as a potential prognostic and decision tool. Me
Autor:
Tugba Akin Telli, Françoise Rothé, Leila Shaza, Caroline Vandeputte, Patrick Flamen, Andrea Pretta, Chiara Senti, Francesco Sclafani, Amélie Deleruelle, Frédéric Hoerner, Silvia Camera, Alain Hendlisz, Amélie Deleporte, Gabriela Critchi, Giacomo Bregni, Elena Trevisi, Pashalina Kehagias, Erwin Woff, Thomas Guiot, Sophia Leduc
Publikováno v:
Web of Science
e16012 Background: Decision making in rCRC patients (pts) who have exhausted all available therapies is challenging. Clinical trials, treatment re-challenge and best supportive care are possible options. There are limited data, however, to predict pt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80884f4bebfa06a71e1471b8cc7f6944
https://publons.com/wos-op/publon/54204212/
https://publons.com/wos-op/publon/54204212/
Autor:
Patrick Flamen, Camilo Garcia, Caroline Vandeputte, Godelieve Machiels, Marianne Paesmans, Martine Piccart, Nicolas Charette, Amélie Deleporte, Alain Hendlisz, Frédéric Hoerner, Marc Lemort, Jean-Luc Engelholm, Ahmad Awada, Philippe Aftimos
Publikováno v:
BMC cancer, 14 (1
BMC Cancer
BMC Cancer
Background: Metastatic colorectal cancer (mCRC) may present various behaviours that define different courses of tumor evolution. There is presently no available tool designed to assess tumor aggressiveness, despite the fact that this is considered to